News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GammaCan International, Inc. (GCAN.OB) Discovers Anti-Angiogenic Properties in Plasma-Derived IgG; Company Files Patent Application Pertaining to Disorders of Neovascularization Including Cancer and Other Diseases


6/28/2007 1:11:29 PM

KIRYAT ONO, Israel & NEW YORK--(BUSINESS WIRE)--GammaCan International, Inc. (“GammaCan” or “the Company”) (OTCBB: GCAN), a developer of proprietary immunotherapies for the treatment of melanoma and other cancers, announced today that its Chief Scientist, Professor Yehuda Shoenfeld, M.D., FRCP, has discovered that gamma-immunoglobulins, or IgG, manufactured from human plasma, contain sub-fractions with potent anti-angiogenic properties which may have application in disorders of neovascularization, including cancer and other diseases. This discovery is the subject of a recent patent application filing with the U.S. Patent and Trademark Office.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES